Original Research
Response-Guided Therapy an Appropriate Tool for Evaluating Treatment Protocols and Costs of Drug Therapies
Employers’ Obesity Initiatives in the Workplace: A Wakeup Call for Health Plans
Michael Naslund, MD, MBA, Michael Eaddy, PharmD, PhD, Susan L. Hogue, PharmD, MPH, Eric J. Kruep, PharmD, MS, Manan B. Shah, PharmD, PhD
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?
Andrea Henry, PharmD, MBA, Goldina Ikezuagu Erowele, PharmD, Uche Anadu Ndefo, PharmD, BCPS, Jackie Milton-Brown, PharmD, Enock Anassi, PharmD, MD, Wendy Green, PharmD, MPA, Adriana Alvidrez, PharmD, BCPS, Alphonsus U. Okpara, PharmD
A Collaborative Approach to Drug Selection, Driven by Clinical Outcomes Excellence
Eric Q. Wu, PhD, Paul E. Greenberg, MA, Rym Ben-Hamadi, MSc, Andrew P. Yu, PhD, Elaine H. Yang, PhD, M. Haim Erder, PhD
Efficacy and Cost-Effectiveness: Escitalopram versus Citalopram
New Strategies Needed to Combat Increasing Costs and Optimize Use of Infused Therapies
Stakeholder Integration Crucial to Improved Patient Outcomes: Lessons from a Health Plan’s Experience
Anna O. D’Souza, PhD, Beth Common, MBA, Roshan Rahnama, MPH, Steven Burch, PhD, Timothy S. Regan, BPharm, RPh
Value-Based Insurance Design: Evolving Strategies to Improve Medication Adherence, Control Healthcare Utilization